References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULiege; Lancellotti, Patrizio ULiege; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 40 (4 ULiège)
Full Text
See detailFaut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l'hypersécrétion est contrôlée médicalement ?
Eroukhmanoff, J; Tejedor, I; Potorac, Iulia ULiege et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 18 (1 ULiège)
Full Text
See detailFrom guidelines to real daily practice : prolactinoma in pregnancy
VROONEN, Laurent ULiege; Potorac, Iulia ULiege; D'Andréa, S et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 16 (0 ULiège)
Full Text
See detailA new clinical presentation of a non-so-rare disease, the Di George syndrome
VROONEN, Laurent ULiege; D'Andrea, S; Tome, M et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 16 (1 ULiège)
Full Text
See detailUtilisation de la cabergoline dans le traitement palliatif de la maladie de Cushing : l'étude Frenchcab
Ferriere, A; Cortet, C; Chanson, P et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 34 (0 ULiège)
Full Text
See detailSomatic mosaicism is implicated in the etiology of XLAG syndrome
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Yuan, Bo et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 15 (1 ULiège)
Full Text
See detailHypogonadism due to a novel inactivating mutation of the luteinizing hormone beta subunit (LHB) gene leading to impaired protein trafficking
Potorac, Iulia ULiege; Rivero-muller, a; Trehan, A et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 20 (3 ULiège)
Full Text
See detailThyroid nodule : metastasis or primary neoplasm ?
PETIGNOT, Sandrine ULiege; PETROSSIANS, Patrick ULiege; VAN DAELE, Daniel ULiege et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 14 (1 ULiège)
See detailThe peroxisome proliferator-activated receptor Alpha (PPARA) is expressed in non-somatotroph pituitary adenomas : a potential therapeutic target ?
Rotondi, S; Polidoro, MA; Morace, R et al

Poster (2016, October)

Detailed reference viewed: 6 (0 ULiège)
Full Text
See detailLe syndrome de De Morsier : une cause congénitale méconnue d'hypopituitarisme
VALDES SOCIN, Hernan Gonzalo ULiege; VERLOES, Alain ULiege; Debray, François-Guillaume ULiege et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 19 (2 ULiège)
Full Text
See detailMaladie de Cushing et kyste de la poche de Rathke : un défi diagnostique
VROONEN, Laurent ULiege; KREUTZ, Julie ULiege; Potorac, Iulia ULiege et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 28 (0 ULiège)
Full Text
See detailHypogonadisme hypogonadotrope anosmique associé à une nouvelle mutation hétérozygote c.937C>T, p.His314Tyr de l'isoforme IIIb du gène FGR1.
VALDES SOCIN, Hernan Gonzalo ULiege; CORMAN, Vinciane ULiege; LIBIOULLE, Cécile ULiege et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 8 (0 ULiège)
See detailThe road from the adenoma valley through the forest of genetic testing in pituitary adenoma
Beckers, Albert ULiege

Scientific conference (2016, October)

Detailed reference viewed: 13 (0 ULiège)
Full Text
Peer Reviewed
See detailT2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac, Iulia ULiege; PETROSSIANS, Patrick ULiege; Daly, Adrian ULiege et al

in Endocrine-Related Cancer (2016), 23(11), 871881

GH-secreting pituitary adenomas can be hypo-, iso- or hyperintense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the ... [more ▼]

GH-secreting pituitary adenomas can be hypo-, iso- or hyperintense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyperintense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypointense adenoma had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyperintense groups (p<0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypointense group (38%) compared with the T2-iso- and hyperintense groups (8% and 3%, respectively; p<0.0001). The response to SSA correlated with the calculated T2-intensity: the lower the T2-weighted intensity, the greater the decrease of random GH (p<0.0001, r=0.22), IGF-1 (p<0.0001, r=0.14) and adenoma volume (p<0.0001, r=0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with the hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly. [less ▲]

Detailed reference viewed: 41 (9 ULiège)
See detailGenetics of pituitary adenomas
Rostomyan, Liliya ULiege; Beckers, Albert ULiege

Scientific conference (2016, September)

Detailed reference viewed: 14 (2 ULiège)
See detailDiagnostic and treatment of acromegaly and gigantism
Rostomyan, Liliya ULiege; Beckers, Albert ULiege

Scientific conference (2016, August)

Detailed reference viewed: 33 (3 ULiège)
Full Text
Peer Reviewed
See detailCharacterization of GPR101 transcripts structure and expression patterns
Trivellin, Giampaolo; Ivana, Bjelobaba; Daly, Adrian ULiege et al

in Journal of Molecular Endocrinology (2016)

Detailed reference viewed: 20 (8 ULiège)
See detailPrise en charge thérapeutique des acromégalies génétiquement déterminées
Beckers, Albert ULiege

Scientific conference (2016, May 20)

Detailed reference viewed: 22 (1 ULiège)